Notable Labs, Ltd. (NASDAQ: NTBL) Stock Competitors & Peer Comparison
See NTBL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NTBL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NTBL | $0.25 | -27.68% | 2.4M | -0.23 | -$1.09 | N/A |
| VRTX | $484.83 | +1.28% | 123.1B | 25.48 | $19.03 | N/A |
| REGN | $768.58 | +1.04% | 79.2B | 16.84 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $867.94 | +2.78% | 54B | 78.33 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $197.30 | +1.98% | 41.9B | -27.91 | -$7.07 | N/A |
| RVMDW | $10.25 | +2.30% | 41.8B | -2.47 | -$4.15 | N/A |
| ONC | $327.53 | +1.40% | 35B | 57.66 | $5.68 | N/A |
| ALNY | $228.72 | +4.44% | 30.6B | 41.21 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
NTBL vs VRTX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, VRTX has a market cap of 123.1B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while VRTX trades at $484.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas VRTX's P/E ratio is 25.48. In terms of profitability, NTBL's ROE is -0.60%, compared to VRTX's ROE of +0.21%. Regarding short-term risk, NTBL is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
NTBL vs REGN Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, REGN has a market cap of 79.2B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while REGN trades at $768.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas REGN's P/E ratio is 16.84. In terms of profitability, NTBL's ROE is -0.60%, compared to REGN's ROE of +0.18%. Regarding short-term risk, NTBL is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
NTBL vs VRNA Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas VRNA's P/E ratio is -102.80. In terms of profitability, NTBL's ROE is -0.60%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, NTBL is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
NTBL vs ARGX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ARGX has a market cap of 54B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ARGX trades at $867.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ARGX's P/E ratio is 78.33. In terms of profitability, NTBL's ROE is -0.60%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, NTBL is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
NTBL vs SGEN Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas SGEN's P/E ratio is -57.19. In terms of profitability, NTBL's ROE is -0.60%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, NTBL is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
NTBL vs RVMD Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, RVMD has a market cap of 41.9B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while RVMD trades at $197.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas RVMD's P/E ratio is -27.91. In terms of profitability, NTBL's ROE is -0.60%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, NTBL is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
NTBL vs RVMDW Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, RVMDW has a market cap of 41.8B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while RVMDW trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas RVMDW's P/E ratio is -2.47. In terms of profitability, NTBL's ROE is -0.60%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, NTBL is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check RVMDW's competition here
BeOne Medicines AG (NASDAQ: ONC)
NTBL vs ONC Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ONC has a market cap of 35B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ONC trades at $327.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ONC's P/E ratio is 57.66. In terms of profitability, NTBL's ROE is -0.60%, compared to ONC's ROE of +0.12%. Regarding short-term risk, NTBL is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
NTBL vs ALNY Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ALNY has a market cap of 30.6B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ALNY trades at $228.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ALNY's P/E ratio is 41.21. In terms of profitability, NTBL's ROE is -0.60%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, NTBL is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
NTBL vs ROIV Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ROIV has a market cap of 25B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ROIV trades at $34.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ROIV's P/E ratio is -35.56. In terms of profitability, NTBL's ROE is -0.60%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, NTBL is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
NTBL vs INCY Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, INCY has a market cap of 24.3B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while INCY trades at $119.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas INCY's P/E ratio is 16.10. In terms of profitability, NTBL's ROE is -0.60%, compared to INCY's ROE of +0.30%. Regarding short-term risk, NTBL is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
NTBL vs BNTX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, BNTX has a market cap of 23.2B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while BNTX trades at $92.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas BNTX's P/E ratio is -19.95. In terms of profitability, NTBL's ROE is -0.60%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, NTBL is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check BNTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
NTBL vs MRNA Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, MRNA has a market cap of 22.3B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while MRNA trades at $56.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas MRNA's P/E ratio is -6.90. In terms of profitability, NTBL's ROE is -0.60%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, NTBL is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check MRNA's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
NTBL vs UTHR Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while UTHR trades at $519.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas UTHR's P/E ratio is 18.57. In terms of profitability, NTBL's ROE is -0.60%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, NTBL is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check UTHR's competition here
Insmed Incorporated (NASDAQ: INSM)
NTBL vs INSM Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, INSM has a market cap of 21.5B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while INSM trades at $99.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas INSM's P/E ratio is -17.22. In terms of profitability, NTBL's ROE is -0.60%, compared to INSM's ROE of -1.30%. Regarding short-term risk, NTBL is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
NTBL vs BGNE Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas BGNE's P/E ratio is -22.55. In terms of profitability, NTBL's ROE is -0.60%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, NTBL is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
NTBL vs DNA-WT Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, NTBL's ROE is -0.60%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, NTBL is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
NTBL vs GMAB Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, GMAB has a market cap of 18B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while GMAB trades at $29.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas GMAB's P/E ratio is 21.05. In terms of profitability, NTBL's ROE is -0.60%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, NTBL is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check GMAB's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
NTBL vs JAZZ Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, JAZZ has a market cap of 16.4B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while JAZZ trades at $261.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas JAZZ's P/E ratio is 20.34. In terms of profitability, NTBL's ROE is -0.60%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, NTBL is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
NTBL vs NBIX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, NBIX has a market cap of 16.2B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while NBIX trades at $161.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas NBIX's P/E ratio is 23.34. In terms of profitability, NTBL's ROE is -0.60%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, NTBL is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check NBIX's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
NTBL vs BBIO Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, BBIO has a market cap of 16.1B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while BBIO trades at $81.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas BBIO's P/E ratio is -21.92. In terms of profitability, NTBL's ROE is -0.60%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, NTBL is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
NTBL vs ASND Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ASND has a market cap of 15.2B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ASND trades at $244.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ASND's P/E ratio is -100.91. In terms of profitability, NTBL's ROE is -0.60%, compared to ASND's ROE of -56.42%. Regarding short-term risk, NTBL is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
NTBL vs EXEL Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, EXEL has a market cap of 14.3B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while EXEL trades at $56.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas EXEL's P/E ratio is 16.98. In terms of profitability, NTBL's ROE is -0.60%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, NTBL is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
NTBL vs KRTX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas KRTX's P/E ratio is -28.09. In terms of profitability, NTBL's ROE is -0.60%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, NTBL is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
NTBL vs ARWR Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ARWR trades at $86.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ARWR's P/E ratio is -38.63. In terms of profitability, NTBL's ROE is -0.60%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, NTBL is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
NTBL vs MDGL Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while MDGL trades at $514.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas MDGL's P/E ratio is -40.17. In terms of profitability, NTBL's ROE is -0.60%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, NTBL is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check MDGL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
NTBL vs BMRN Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while BMRN trades at $59.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas BMRN's P/E ratio is 28.80. In terms of profitability, NTBL's ROE is -0.60%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, NTBL is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
NTBL vs TECH Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while TECH trades at $72.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas TECH's P/E ratio is 37.11. In terms of profitability, NTBL's ROE is -0.60%, compared to TECH's ROE of +0.05%. Regarding short-term risk, NTBL is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
NTBL vs RNAM Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas RNAM's P/E ratio is -17.39. In terms of profitability, NTBL's ROE is -0.60%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, NTBL is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
NTBL vs AXSM Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, AXSM has a market cap of 11B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while AXSM trades at $212.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas AXSM's P/E ratio is -55.57. In terms of profitability, NTBL's ROE is -0.60%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, NTBL is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check AXSM's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
NTBL vs SMMT Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, SMMT has a market cap of 10.8B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while SMMT trades at $13.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas SMMT's P/E ratio is -8.46. In terms of profitability, NTBL's ROE is -0.60%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, NTBL is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
NTBL vs HALO Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, HALO has a market cap of 9.9B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while HALO trades at $83.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas HALO's P/E ratio is 18.09. In terms of profitability, NTBL's ROE is -0.60%, compared to HALO's ROE of +1.26%. Regarding short-term risk, NTBL is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
NTBL vs CYTK Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, CYTK has a market cap of 9.8B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while CYTK trades at $78.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas CYTK's P/E ratio is -13.52. In terms of profitability, NTBL's ROE is -0.60%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, NTBL is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check CYTK's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
NTBL vs KRYS Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, KRYS has a market cap of 9.6B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while KRYS trades at $325.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas KRYS's P/E ratio is 40.82. In terms of profitability, NTBL's ROE is -0.60%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, NTBL is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
NTBL vs RXDX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas RXDX's P/E ratio is -56.47. In terms of profitability, NTBL's ROE is -0.60%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, NTBL is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
NTBL vs ABVX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ABVX trades at $125.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ABVX's P/E ratio is -65.73. In terms of profitability, NTBL's ROE is -0.60%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, NTBL is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
NTBL vs NUVL Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas NUVL's P/E ratio is -21.79. In terms of profitability, NTBL's ROE is -0.60%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, NTBL is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check NUVL's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
NTBL vs SYRE Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, SYRE has a market cap of 9.1B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while SYRE trades at $104.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas SYRE's P/E ratio is -53.51. In terms of profitability, NTBL's ROE is -0.60%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, NTBL is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check SYRE's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
NTBL vs IONS Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, IONS has a market cap of 9B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while IONS trades at $54.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas IONS's P/E ratio is -31.51. In terms of profitability, NTBL's ROE is -0.60%, compared to IONS's ROE of -1.11%. Regarding short-term risk, NTBL is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check IONS's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
NTBL vs CRNX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while CRNX trades at $84.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas CRNX's P/E ratio is -16.37. In terms of profitability, NTBL's ROE is -0.60%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, NTBL is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check CRNX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
NTBL vs PRAX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, PRAX has a market cap of 8.9B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while PRAX trades at $319.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas PRAX's P/E ratio is -23.88. In terms of profitability, NTBL's ROE is -0.60%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, NTBL is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check PRAX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
NTBL vs PTGX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while PTGX trades at $137.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas PTGX's P/E ratio is -75.87. In terms of profitability, NTBL's ROE is -0.60%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, NTBL is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
NTBL vs IMGN Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas IMGN's P/E ratio is -111.55. In terms of profitability, NTBL's ROE is -0.60%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, NTBL is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check IMGN's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
NTBL vs KYMR Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, KYMR has a market cap of 8.7B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while KYMR trades at $105.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas KYMR's P/E ratio is -29.88. In terms of profitability, NTBL's ROE is -0.60%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, NTBL is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check KYMR's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
NTBL vs BPMC Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas BPMC's P/E ratio is -51.58. In terms of profitability, NTBL's ROE is -0.60%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, NTBL is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check BPMC's competition here
Alkermes plc (NASDAQ: ALKS)
NTBL vs ALKS Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ALKS has a market cap of 8.3B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ALKS trades at $49.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ALKS's P/E ratio is 52.22. In terms of profitability, NTBL's ROE is -0.60%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, NTBL is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ALKS's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
NTBL vs APGE Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while APGE trades at $134.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas APGE's P/E ratio is -31.00. In terms of profitability, NTBL's ROE is -0.60%, compared to APGE's ROE of -0.33%. Regarding short-term risk, NTBL is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
NTBL vs CERE Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas CERE's P/E ratio is -16.47. In terms of profitability, NTBL's ROE is -0.60%, compared to CERE's ROE of -0.72%. Regarding short-term risk, NTBL is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check CERE's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
NTBL vs PCVX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, PCVX has a market cap of 8.1B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while PCVX trades at $55.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas PCVX's P/E ratio is -8.13. In terms of profitability, NTBL's ROE is -0.60%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, NTBL is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check PCVX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
NTBL vs IMVT Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while IMVT trades at $39.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas IMVT's P/E ratio is -14.71. In terms of profitability, NTBL's ROE is -0.60%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, NTBL is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check IMVT's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
NTBL vs TGTX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, TGTX has a market cap of 7.6B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while TGTX trades at $49.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas TGTX's P/E ratio is 18.07. In terms of profitability, NTBL's ROE is -0.60%, compared to TGTX's ROE of +0.84%. Regarding short-term risk, NTBL is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check TGTX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
NTBL vs RYTM Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, RYTM has a market cap of 7.6B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while RYTM trades at $110.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas RYTM's P/E ratio is -35.37. In terms of profitability, NTBL's ROE is -0.60%, compared to RYTM's ROE of -2.01%. Regarding short-term risk, NTBL is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check RYTM's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
NTBL vs IBRX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while IBRX trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas IBRX's P/E ratio is -8.53. In terms of profitability, NTBL's ROE is -0.60%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, NTBL is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
NTBL vs MTSR Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas MTSR's P/E ratio is -23.58. In terms of profitability, NTBL's ROE is -0.60%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, NTBL is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check MTSR's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
NTBL vs COGT Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, COGT has a market cap of 7.2B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while COGT trades at $42.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas COGT's P/E ratio is -20.03. In terms of profitability, NTBL's ROE is -0.60%, compared to COGT's ROE of -0.83%. Regarding short-term risk, NTBL is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check COGT's competition here
Merus N.V. (NASDAQ: MRUS)
NTBL vs MRUS Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas MRUS's P/E ratio is -17.05. In terms of profitability, NTBL's ROE is -0.60%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, NTBL is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
NTBL vs ACLX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ACLX's P/E ratio is -28.27. In terms of profitability, NTBL's ROE is -0.60%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, NTBL is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
NTBL vs RETA Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas RETA's P/E ratio is -66.29. In terms of profitability, NTBL's ROE is -0.60%, compared to RETA's ROE of +0.47%. Regarding short-term risk, NTBL is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check RETA's competition here
Erasca, Inc. (NASDAQ: ERAS)
NTBL vs ERAS Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ERAS has a market cap of 6.5B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ERAS trades at $18.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ERAS's P/E ratio is -20.02. In terms of profitability, NTBL's ROE is -0.60%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, NTBL is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ERAS's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
NTBL vs MIRM Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while MIRM trades at $105.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas MIRM's P/E ratio is -7.77. In terms of profitability, NTBL's ROE is -0.60%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, NTBL is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check MIRM's competition here
CG Oncology Inc. (NASDAQ: CGON)
NTBL vs CGON Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while CGON trades at $72.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas CGON's P/E ratio is -31.08. In terms of profitability, NTBL's ROE is -0.60%, compared to CGON's ROE of -0.23%. Regarding short-term risk, NTBL is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check CGON's competition here
Belite Bio, Inc (NASDAQ: BLTE)
NTBL vs BLTE Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while BLTE trades at $158.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas BLTE's P/E ratio is -84.76. In terms of profitability, NTBL's ROE is -0.60%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, NTBL is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check BLTE's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
NTBL vs CNTA Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas CNTA's P/E ratio is -22.63. In terms of profitability, NTBL's ROE is -0.60%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, NTBL is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
NTBL vs XENE Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, XENE has a market cap of 6.2B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while XENE trades at $64.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas XENE's P/E ratio is -13.68. In terms of profitability, NTBL's ROE is -0.60%, compared to XENE's ROE of -0.49%. Regarding short-term risk, NTBL is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
NTBL vs LGND Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while LGND trades at $302.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas LGND's P/E ratio is 36.28. In terms of profitability, NTBL's ROE is -0.60%, compared to LGND's ROE of +0.16%. Regarding short-term risk, NTBL is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check LGND's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
NTBL vs TVTX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while TVTX trades at $62.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas TVTX's P/E ratio is -139.47. In terms of profitability, NTBL's ROE is -0.60%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, NTBL is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check TVTX's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
NTBL vs PTCT Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while PTCT trades at $69.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas PTCT's P/E ratio is -29.70. In terms of profitability, NTBL's ROE is -0.60%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, NTBL is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check PTCT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
NTBL vs SRRK Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while SRRK trades at $47.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas SRRK's P/E ratio is -13.33. In terms of profitability, NTBL's ROE is -0.60%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, NTBL is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
NTBL vs CDTX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas CDTX's P/E ratio is -19.77. In terms of profitability, NTBL's ROE is -0.60%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, NTBL is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
NTBL vs ABCM Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, NTBL's ROE is -0.60%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, NTBL is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
NTBL vs ISEE Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ISEE's P/E ratio is -22.44. In terms of profitability, NTBL's ROE is -0.60%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, NTBL is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
NTBL vs APLS Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas APLS's P/E ratio is 38.35. In terms of profitability, NTBL's ROE is -0.60%, compared to APLS's ROE of +0.40%. Regarding short-term risk, NTBL is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check APLS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
NTBL vs CRSP Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while CRSP trades at $52.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas CRSP's P/E ratio is -10.26. In terms of profitability, NTBL's ROE is -0.60%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, NTBL is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check CRSP's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
NTBL vs ACAD Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ACAD has a market cap of 4.9B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ACAD trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ACAD's P/E ratio is 14.12. In terms of profitability, NTBL's ROE is -0.60%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, NTBL is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
NTBL vs DYN Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while DYN trades at $26.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas DYN's P/E ratio is -8.13. In terms of profitability, NTBL's ROE is -0.60%, compared to DYN's ROE of -0.64%. Regarding short-term risk, NTBL is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check DYN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
NTBL vs DFTX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, DFTX has a market cap of 4.8B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while DFTX trades at $44.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas DFTX's P/E ratio is N/A. In terms of profitability, NTBL's ROE is -0.60%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, NTBL is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check DFTX's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
NTBL vs EWTX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while EWTX trades at $44.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas EWTX's P/E ratio is -27.10. In terms of profitability, NTBL's ROE is -0.60%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, NTBL is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
NTBL vs TERN Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas TERN's P/E ratio is -51.41. In terms of profitability, NTBL's ROE is -0.60%, compared to TERN's ROE of -0.20%. Regarding short-term risk, NTBL is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check TERN's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
NTBL vs DNTH Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, DNTH has a market cap of 4.7B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while DNTH trades at $112.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas DNTH's P/E ratio is -27.24. In terms of profitability, NTBL's ROE is -0.60%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, NTBL is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check DNTH's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
NTBL vs CAI Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while CAI trades at $16.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas CAI's P/E ratio is -90.48. In terms of profitability, NTBL's ROE is -0.60%, compared to CAI's ROE of +0.06%. Regarding short-term risk, NTBL is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
NTBL vs MANE Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while MANE trades at $111.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas MANE's P/E ratio is -35.31. In terms of profitability, NTBL's ROE is -0.60%, compared to MANE's ROE of -0.84%. Regarding short-term risk, NTBL is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
NTBL vs FOLD Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas FOLD's P/E ratio is -161.00. In terms of profitability, NTBL's ROE is -0.60%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, NTBL is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check FOLD's competition here
Celcuity Inc. (NASDAQ: CELC)
NTBL vs CELC Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while CELC trades at $92.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas CELC's P/E ratio is -23.83. In terms of profitability, NTBL's ROE is -0.60%, compared to CELC's ROE of -2.45%. Regarding short-term risk, NTBL is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check CELC's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
NTBL vs AKRO Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas AKRO's P/E ratio is -14.57. In terms of profitability, NTBL's ROE is -0.60%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, NTBL is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
NTBL vs ALPN Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ALPN's P/E ratio is -101.52. In terms of profitability, NTBL's ROE is -0.60%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, NTBL is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ALPN's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
NTBL vs ELVN Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ELVN has a market cap of 4.3B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ELVN trades at $59.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ELVN's P/E ratio is -35.75. In terms of profitability, NTBL's ROE is -0.60%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, NTBL is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ELVN's competition here
Opthea Limited (NASDAQ: OPT)
NTBL vs OPT Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas OPT's P/E ratio is -1.52. In terms of profitability, NTBL's ROE is -0.60%, compared to OPT's ROE of +1.18%. Regarding short-term risk, NTBL is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
NTBL vs PRTC Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas PRTC's P/E ratio is -3.78. In terms of profitability, NTBL's ROE is -0.60%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, NTBL is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
NTBL vs MRTX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas MRTX's P/E ratio is -4.82. In terms of profitability, NTBL's ROE is -0.60%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, NTBL is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check MRTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
NTBL vs ADPT Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ADPT trades at $24.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ADPT's P/E ratio is -45.56. In terms of profitability, NTBL's ROE is -0.60%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, NTBL is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ADPT's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
NTBL vs VKTX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while VKTX trades at $33.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas VKTX's P/E ratio is -8.09. In terms of profitability, NTBL's ROE is -0.60%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, NTBL is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
NTBL vs DNLI Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, DNLI has a market cap of 3.9B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while DNLI trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas DNLI's P/E ratio is -8.48. In terms of profitability, NTBL's ROE is -0.60%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, NTBL is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check DNLI's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
NTBL vs CPRX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas CPRX's P/E ratio is 12.30. In terms of profitability, NTBL's ROE is -0.60%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, NTBL is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
NTBL vs RYZB Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas RYZB's P/E ratio is -57.86. In terms of profitability, NTBL's ROE is -0.60%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, NTBL is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
NTBL vs CBAY Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas CBAY's P/E ratio is -32.81. In terms of profitability, NTBL's ROE is -0.60%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, NTBL is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check CBAY's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
NTBL vs ORKA Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while ORKA trades at $97.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas ORKA's P/E ratio is -50.10. In terms of profitability, NTBL's ROE is -0.60%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, NTBL is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check ORKA's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
NTBL vs TNGX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, TNGX has a market cap of 3.6B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while TNGX trades at $28.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas TNGX's P/E ratio is -34.69. In terms of profitability, NTBL's ROE is -0.60%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, NTBL is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check TNGX's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
NTBL vs SWTX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas SWTX's P/E ratio is -13.78. In terms of profitability, NTBL's ROE is -0.60%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, NTBL is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check SWTX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
NTBL vs TLX Comparison August 2026
Notable Labs, Ltd. (NASDAQ: NTBL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NTBL stands at 2.4M. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, NTBL is priced at $0.25 on the NASDAQ, while TLX trades at $10.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NTBL currently has a P/E ratio of -0.23, whereas TLX's P/E ratio is -566.30. In terms of profitability, NTBL's ROE is -0.60%, compared to TLX's ROE of -0.02%. Regarding short-term risk, NTBL is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for NTBL.Check TLX's competition here